These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12086391)

  • 21. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis.
    Mahmud E; Bromberg-Marin G; Palakodeti V; Ang L; Creanga D; Demaria AN
    J Am Coll Cardiol; 2008 Jun; 51(25):2385-95. PubMed ID: 18565394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-eluting stents: clinical experiences and perspectives.
    Grube E; Gerckens U; Buellesfeld L
    Minerva Cardioangiol; 2002 Oct; 50(5):469-73. PubMed ID: 12384629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Restenosis in percutaneous coronary intervention--is drug-eluting stent the answer?
    Lim VY; Lim YL
    Singapore Med J; 2003 Sep; 44(9):482-7. PubMed ID: 14740779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease.
    van Domburg RT; Lemos PA; Takkenberg JJ; Liu TK; van Herwerden LA; Arampatzis CA; Smits PC; Daemen J; Venema AC; Serruys PW; Bogers AJ
    Eur Heart J; 2005 Apr; 26(7):675-81. PubMed ID: 15637087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Status of drug-eluting coronary stents.
    Chodosh A; Korr KS; Burtt D
    Med Health R I; 2008 Oct; 91(10):309-12, 314. PubMed ID: 19044106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.
    Beijk MA; Piek JJ
    Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. All drug-eluting stents are equal, but some drug-eluting stents are more equal than others.
    Strauss BH
    J Am Coll Cardiol; 2006 Oct; 48(7):1310-1. PubMed ID: 17010787
    [No Abstract]   [Full Text] [Related]  

  • 29. Impact of three or more sirolimus-eluting stents versus paclitaxel-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention.
    Chu WW; Kuchulakanti PK; Torguson R; Wang B; Clavijo LC; Suddath WO; Pichard AD; Satler LF; Kent KM; Waksman R
    Catheter Cardiovasc Interv; 2006 Jul; 68(1):62-6. PubMed ID: 16755592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Choosing a drug-eluting stent: a comparison between CYPHER and TAXUS.
    Perin EC
    Rev Cardiovasc Med; 2005; 6 Suppl 1():S13-21. PubMed ID: 15665793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents.
    Elezi S; Dibra A; Mehilli J; Pache J; Wessely R; Schömig A; Kastrati A
    J Am Coll Cardiol; 2006 Oct; 48(7):1304-9. PubMed ID: 17010786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymer-based paclitaxel-eluting stents in percutaneous coronary intervention: a review of the TAXUS trials.
    Halkin A; Stone GW
    J Interv Cardiol; 2004 Oct; 17(5):271-82. PubMed ID: 15491330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-eluting stents substantially lower rate of restenosis.
    Rollins G
    Rep Med Guidel Outcomes Res; 2003 Oct; 14(20):7-9. PubMed ID: 14584494
    [No Abstract]   [Full Text] [Related]  

  • 34. Hybrid coronary revascularization in the era of drug-eluting stents.
    Murphy GJ; Bryan AJ; Angelini GD
    Ann Thorac Surg; 2004 Nov; 78(5):1861-7. PubMed ID: 15511503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-stent restenosis: 3 novel solutions show promise for heart patients. Stopping regrowth of plaque inside stents is a priority in reducing the need for repeat revascularizations.
    Duke Med Health News; 2007 Mar; 13(3):3-4. PubMed ID: 17385240
    [No Abstract]   [Full Text] [Related]  

  • 36. Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study.
    Tomai F; Reimers B; De Luca L; Galassi AR; Gaspardone A; Ghini AS; Ferrero V; Favero L; Gioffrè G; Prati F; Tamburino C; Ribichini F
    Diabetes Care; 2008 Jan; 31(1):15-9. PubMed ID: 17909090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
    Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. American Heart Association 2001 scientific sessions: late-breaking science-drug-eluting stents.
    Fox R
    Circulation; 2001 Nov; 104(21):E9052. PubMed ID: 11727731
    [No Abstract]   [Full Text] [Related]  

  • 39. Degradable, drug-eluting stents: a new frontier for the treatment of coronary artery disease.
    Kohn J; Zeltinger J
    Expert Rev Med Devices; 2005 Nov; 2(6):667-71. PubMed ID: 16293093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding the drug-eluting stent trials.
    Coolong A; Kuntz RE
    Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.